Accelerate biotech innovation with quantum-powered discovery
Quantum-Aided Drug Design: A big-time discovery boost, no matter the size of your team
PolarisQB offers turnkey solutions that give biotech companies access to the most powerful drug discovery methods available today, even when internal resources are limited.
Using our QuADD (Quantum-Aided Drug Design) solutions, biotech companies can explore vast chemical spaces and optimize candidate molecules in a fraction of the time required by conventional methods and tools.
Get a head start on novel, hard-to-find molecules
All of our solutions integrate seamlessly into your discovery pipeline, allowing your team to apply your preferred discovery strategy.
-
First-In-Class Mode: Prioritize novelty.
-
Best-In-Class Mode: Prioritize similarity to template structure.
-
Preferred-Library Mode: Limit your search to your choice of commercial libraries.
-
Scaffold-Hopping Mode: Hold part of the molecule constant while exploring other parts.
Apply to any protein target — no training data required
Unlike AI solutions that are constrained by available training data, our quantum-aided solutions are not bound by the constraints of training data. Using physics-based calculations with no need for parametrization, they can be confidently applied to any drug target with a known 3D structure, including those that are novel or have limited existing data.
Maintain explainability and confidence as you search uncharted spaces
Our QuADD solutions apply physics-based models that provide explainable output, delivering results that chemists can clearly understand and trust.
Find your breakthrough molecule with quantum computing power
What our customers are saying
“Our collaboration with PolarisQB led to rapid identification of viable drug candidates, significantly accelerating our research timeline towards quality solutions for hard to tackle or neglected diseases affecting women’s health.”
“Using quantum computing and advanced AI technology with PolarisQB, we explored a chemical space that was previously undefined, leading to the discovery of novel molecules for our primary program of Optimizing the Aging and Longevity Molecular Process much faster than expected.”
“This partnership represents the ultimate ambition for collaboration between biology and technology, where the full diversity of newly identified disease targets can be married to the most logical and rapid method of finding small molecule drugs.”
